Companies › Eledon Pharmaceuticals
1 active drug program in 3 registered trials: 3 Phase 1; Genitourinary, Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tegoprubart (AT-1501) CD40 ligand inhibitor | CD40LG | Phase 1 | Prevention of Rejection in Kidney Transplant; Type 1 Diabetes Mellitus; Diabete Type 1 | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05027906 | Tegoprubart (AT-1501) | Phase 1 | Prevention of Rejection in Kidney Transplant | Genitourinary | Jan 2027 |
| NCT06305286 | Tegoprubart (AT-1501) | Phase 1 | Type 1 Diabetes Mellitus | Metabolic and endocrine | Mar 2029 |
| NCT07592000 | Tegoprubart (AT-1501) | Phase 1 | Diabete Type 1 | Genitourinary | Jan 2030 |
Cash and short-term investments of $89m on 2026-06-30; operating cash outflow about $92m a year; runway about 12 months at that burn, to Jun 2027
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.